TA-CIN
- Generic Name
- TA-CIN
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
TA-CIN is a subunit vaccine comprising L2/E6/E7 proteins from Human Papillomavirus (HPV16), designed to generate a strong cellular immune response against HPV-infected cells.
- Indication
Investigated for use/treatment in cervical dysplasia/cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer
Phase 1
Active, not recruiting
- Conditions
- HPV16 Associated Cervical Cancer
- Interventions
- First Posted Date
- 2015-04-01
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Target Recruit Count
- 14
- Registration Number
- NCT02405221
- Locations
- 🇺🇸
Women & Infants Center, University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath